cyrilzakka/clinical-trials huggingface dataset:
Effects of Dance on the Turning Characteristics of Patients With Parkinson's Disease

The proposed control intervention trial, aims to analyse the effects of Dance in the turning characteristics in patients with Parkinson Disease (PD) using three- dimensional (3D) analysis during the timed up and go (TUG) test.

Experimental Design: control intervention non-randomized trial. Search Location: University of Wolverhaptom, Walsall Campus, United Kingdom; Federal University of Rio Grande do Sul, Brazil.

Participants: 15 adults aged between 50 and 80 years, with a clinical diagnosis of idiopathic PD, staging between 1 and 4 of the Hoehn \& Yahr Scale, recruited from Dance for Parkinson's Projects, West-Midlands County, United Kingdom, and from Parkinson's UK (United Kingdom).

Interventions: Dance intervention for 3 months, 2 times/week (1 instructor lecture session and 1 home session following a prepared video), 2 hours per week. Controls, not alter their personal lifestyle, but undergo the same testing as the exercise intervention group.

Outcomes: clinical-functional parameters (number of steps and total time of the 180 turning phase of the Timed up and go Test - TUG - and biomechanics parameter - girdle dissociation) Data Analysis: Data will be described by average values and standard deviation values. All statistical analyses will be carried out using SPSS version 23, and Microsoft Excel Program version 16.44. The significance level is set at p\<0.05. The Cohen's d is going to be used to predict effect interpreted as small d= 0.2, medium d=0.5, and large d=0.8, and 95% confidence intervals were presented.

Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis of PD according to the London Brain Bank Criteria;
* Able to understand the verbal instructions for the tests and to walk;
* Or attempt to walk independently with no walking aid.

Exclusion Criteria:

* Recent surgeries,
* Deep brain stimulation (DBS);
* Severe heart diseases, uncontrolled hypertension, myocardial infarction within a period of less than one year;
* Fitted with a pacemaker;
* Prostheses in the lower limbs;
* Stroke or other associated neurological diseases.
Inflammation in Vascular Disease

Increasing evidence suggests that systemic low-grade inflammation may be a driving force of cardiometabolic complications, such as vascular dysfunction, atherosclerosis and ischemic heart disease. Thus, we will investigate the role of inflammation in cardiovascular disease.

Vascular reconstruction surgeries usually require a small piece of the vessel wall to be excised. The excised vessel is generally discarded as medical waste: however, for patients participating in the study, the excised tissue will be placed in saline and collected for research use.

Tissue collected from individuals undergoing vascular surgery associated with peripheral arterial diseases, aneurysm and/or other manifestations of atherosclerosis, vascular tissue will be cultured ex vivo in the presence or absence of therapeutic agents, to determine if these attenuate the inflammation associated with the atherosclerotic phenotype. Furthermore, the protocol will also be carried out using vascular tissue from control patients, which have undergone vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc).

Eligibility Criteria:
Inclusion Criteria:

* Patient is planned to undergo vascular surgery.
* Signed informed consent has been obtained from the patient.

Exclusion Criteria:

* Patient has difficulty to understand information.
* Patients under 18 years of age.
* Patients participating in any drug-related study.
Comparison of Critical Flicker Fusion Versus Automated Visual Fields in the Detection of Early Glaucoma

The purpose of this study is to evaluate if critical flicker fusion is a more reliable method for detection of early glaucoma compared to automated visual fields in comparison to subjects without evidence of glaucoma or optic nerve disease.

Our hypothesis is that critical flicker fusion (CFF) is a more reliable method for detection of early glaucoma compared to automated visual fields in comparison to subjects without evidence of glaucoma or optic nerve disease. We aim to evaluate the structure of the optic nerve and compare it to results of visual fields and CFF. The CFF will also be correlated with intraocular pressure (IOP) measurements to observe if it may be more closely related than visual fields. This may become an additional tool to detect glaucoma in those with unreliable visual fields or who are unable to perform a visual field from physical or mental limitations.

Eligibility Criteria:
Inclusion:

* Glaucoma Suspects:
* Abnormal optic disc appearance with increased cup to disc ratio, or
* Increased intraocular pressure \>21 in either eye
* Control Subjects:
* Normal appearing optic discs
* Normal intraocular pressure (\<21)

Exclusion:

* Other ocular pathology
* History of seizures or epilepsy
Effect of Menopause Relief EP-40 in Women With Menopausal Symptoms

This study compares the efficacy of a fixed combination of black cohosh (EP-40) and Rhodiola rosea (EPR-7) with low (6.5 mg) and high doses (500 mg) of a standardized black cohosh extract only in adult woman with menopausal complaints.

Due to the problems caused by Hormone Replacement Therapy with chemical entities, some medicinal plants used in the traditional systems of medicine have shown immense potential in non-hormonal treatment of menopausal symptoms without major adverse events. We hypothesize that Menopause Relief EP-40 (a fixed combination of Cimicifuga EP-40 and Rhodiola EPR-7 extracts) will significantly relieve menopausal complaints such as hot flushes, profuse sweating hot flushes, excessive perspiration, night sweats, sleep disorders, nervousness, mood swings, physical and mental fatigue as compared to EP-40® capsules or placebo in adult females in menopause.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of menopausal female climacteric states (N95.1 according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision, ICD-10, Version for 2014) which is characterized by symptoms such as flushing, sleeplessness, headache, lack of concentration associated with menopause, etc
* Patients suffering from menopausal syndrome with neurovegetative components which have been stable anamnestically during the last 2 weeks
* No medication taken for management of menopausal syndrome with neurovegetative components during the last 4 weeks
* Ability to understand and provide signed informed consent
* Ability to participate in the study
* In some cases, diagnosis should be confirmed by blood tests of follicle-stimulating hormone (≥ 40 IU/L) \[postmenopausal status\], thyroid function with normal serum free T4 (fT4), estrogen (estrodiol levels) \[premenopausal 30-400 pg/mL; after menopause \<30 pg/mL\]

Exclusion Criteria:

* subjects with previous or current psychological disease that could interfere with their ability to participate in the study
* anamnestic or current alcohol or drug abuse
* concomitant treatment with psychotropic (in particular benzodiazepines, antidepressants, hypnotics or neuroleptics, tamoxifen, clomiphene, and danazol) or hormonally acting drugs such as hormone replacement therapy (HRT)
* hyperthyroidism
* malignant tumors
* continuous climacteric bleeding and complaints related to myomas
* patients who have taken another experimental drug within a 4-week period prior to the trial
* pregnancy/lactation
* serious internal disease
* previous organ transplantation
* premenopausal women with insufficient contraceptive protection
* hypersensitivity to one of the ingredients of the trial medication
* a body mass index of \>30
Long Term Effect of AIT in Children

The present study will investigate the long term effect of allergen immunotherapy in a real-life study in children with allergy undergoing subcutaneous or sublingual immunotherapy with grass pollen, birch, house dust mites or venom.

The study will include children aged 5- 18 years who are treated with immunotherapy at Hans Christian Andersen Children' Hospital, Odense University Hospital.

Informed consent to be registered in a database and to receive a questionnaire 5 and 10 years after end of treatment are obtained before start of immunotherapy.

Base line data include information from the patient record: symptoms, medication, blood test and skin prick test results. During treatment effect, medication use, lung function and adverse events are monitored systematically once a year.

The questionnaires 5 and 10 years after end of treatment will focus on allergy symptoms, use of medication and asthma symptoms.

Eligibility Criteria:
Inclusion Criteria: treated with allergen immunotherapy at HCA Children'sHospital, Odense University Hospital -

Exclusion Criteria: received less than 12 months of treatment with allergen immunotherapy

-
M-gCBT for Women With Provoked Localized Vulvodynia

The purpose of this study is to learn more about Mindfulness based Group Cognitive Behavior Therapy (M-gCBT) as a treatment for Provoked Localized Vulvodynia (PLV). M-gCBT is a counseling technique that has been shown to reduce pain and anxiety with other medical conditions, including chronic pain conditions. The investigators wish to see if participation in M-gCBT course will help reduce anxiety, fear, and pain in women with PLV greater than education alone. Both techniques use a group setting including other women with PLV. "Mindfulness-Based Group Cognitive Behavior Therapy for Women with Localized Vulvodynia" is a study designed to learn more about the use of mindfulness based group cognitive behavior therapy for PLV pain and anxiety over education alone. Participants will be randomized to one of two groups: mindfulness based cognitive behavior therapy or group education seminars.

M-gCBT is a type of counseling that teaches women to have more control over their pain. Educational seminars teach women about the different aspects of PLV that affect emotional and physical health. Both groups will be given a binder containing course material at the first session and homework at each session that you will be asked to complete. The group education seminars will include an informational video clip reviewing an aspect of PLV and sexuality and will be followed by a group discussion facilitated by an instructor. Each session will involve a teacher and a small group of 6 to 12 women with PLV. Additionally, women in both groups will be asked to perform a weekly test to measure pain and to complete a daily diary.

Eligibility Criteria:
Inclusion Criteria:

1. Reported dyspareunia for at least 6 months in non-pregnant, healthy women over aged 18-45 years old meeting Friedrich's criteria for PLV.51
2. Qtip Test51-52, 54 mean verbal rating score of ≥4/10 in 4 of 6 defined points of the vestibule (2, 4, 6, 8, 10, 12 o'clock), and have received a Qtip Test score of verbal ≤ 2/10 for the labia majora and minora, intra labial sulcus, and perineum.
3. Ability to insert a regular Tampax® tampon
4. Baseline tampon test pain score ≥80mm
5. Phone access
6. Lives within 60 miles with reliable transportation

Exclusion Criteria:

1. Pregnancy
2. Active counseling or mindfulness training (within 6 months of study)
3. Any other clinical reason for dyspareunia (endometriosis pain, chronic pelvic pain, vulvar dermatoses such as psoriasis, lichen sclerosus, etc).
4. Impaired cognition or disruptive behavior not conducive to group dynamic
5. Planned long term travel or surgery during study period
6. Unable or unwilling to complete baseline assessments or agree to be randomized.
7. Axis 2 diagnosis, chronic substance abuse, suicidality or disruptive to group dynamic
8. Non-English speaking
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer

This is a multi-center, open label, randomized study. Patients will be randomized to one of the following arms with an allocation ratio of 3:1, respectively: Arm A: CP-675,206 + neoadjuvant hormone therapy (NHT) OR Arm B: neoadjuvant hormone therapy. After randomization, patients will receive study treatment for three cycles (one cycle is defined as 28 days). After completion of three cycles, patients will undergo a prostatectomy and pathology assessments will be completed at a central laboratory, the Armed Forces Institute of Pathology (AFIP) in Washington, DC.


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed adenocarcinoma of the prostate, previously untreated
* Potential candidate for radical prostatectomy on the basis of the patient's general medical condition, performance status, and life expectancy
* Potential candidate for NHT prior to prostatectomy, including high or intermediate risk of recurrence, based on an estimated risk of biochemical recurrence: High risk category: PSA \>20 or Gleason score 8 or cT2c/cT3 OR Intermediate risk category: PSA \>10 and d20 or Gleason score 7 or cT2b
* No evidence of metastatic disease by physical examination, bone scan, and computed tomography, or MRI, of the abdomen and pelvis
* Age \> 18 years
* ECOG performance status 0-1
* Adequate bone marrow, hepatic, and renal function determined within 2 weeks prior to starting therapy
* Availability of prostatectomy specimen for histological analysis at the Armed Forces Institute of Pathology

Exclusion Criteria:

* Prior hormone therapy, radiation, chemotherapy, or immunologic therapy for prostate cancer
* History of, or significant risk for, chronic inflammatory or autoimmune disease
* Potential requirement for systemic corticosteroids before surgery based on prior history
* History of autoimmune colitis or chronic GI conditions associated with diarrhea or bleeding, or current acute colitis of any origin
* Any serious uncontrolled medical disorder or active infection which would impair ability to receive study treatment and subsequent prostatectomy
* Coexisting malignancies except basal or squamous cell carcinoma of the skin
COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic

Multicenter observational retrospective cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients from the first and the second wave of the pandemic.

CoVAPid2 is a multicenter retrospective observational cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients from the first and the second wave of the pandemic. Patients with confirmed SARS-CoV-2 community-acquired pneumonia and receiving invasive mechanical ventilation for more than 48h in the participating ICUs from the start of COVID pandemic are eligible for this study. Consecutive patients will be included from the beginning of the first wave (starting on 01-01-2020, data already collected in the CoVAPid1 study) and the second wave (starting on 10-01-2020). 10-20 patients per wave will be included in each center. VAT and VAP are defined using clinical, radiological and quantitative microbiological criteria.

Eligibility Criteria:
Inclusion Criteria:

* Major (18 years and older)
* Admitted to the ICU
* Intubated and mechanically ventilated for more than 48 hours
* With a confirmed community-acquired SARS-CoV2 pneumonia

Exclusion Criteria:

* Refusal to participate
* Lack of social security coverage
Effects of Monitoring Blood Pressure During Pregnancy

In this study, at least 400 women with high-risk of pregnancy hypertension will use a wearable device to monitor the blood pressure during gestational age from 12 weeks to 28weeks. The observed outcomes including maternal and offspring. Participants were from three hospital including Shanghai Xinhua Hospital, Jiaxing Maternal and Child Health Hospital and Peking University Third Hospital. Pregnant women were randomly divided into control group (routine delivery examination group) and intervention group (routine delivery examination group + use of wearable blood pressure monitoring device group), 200 cases each.


Eligibility Criteria:
Inclusion Criteria:

* Women with a single pregnancy before 12 weeks of pregnancy
* The presence of any of the following risk factors: age \> 30 years, a history of eclampsia, a family history of eclampsia, obesity (BMI ≥ 30 Kg/m2), and a history of gestational hyperglycemia (pregestational type 1 and type 2 diabetes; gestational manifest diabetes and gestational diabetes requiring insulin treatment), preexisting chronic hypertension, kidney disease, and autoimmune diseases such as systemic lupus erythematosus and antiphospholipid syndrome.
* Signed the informed consent can be continuously followed up.
* Permanent population living in the study area.
* All subjects received routine antenatal examination and treatment.

Exclusion Criteria:

* Termination of pregnancy before 20 weeks
* Withdraw from the study
* Lost visitors
Diabetes Genome Project: A Prospective Registry to Identify Genetic Variation Among Diabetic Patients

Previous scientific research has found multiple genes that affect the risk for developing heart disease or complications during the treatment of heart disease. Less is currently known about how patients with heart disease may differ on the basis of other ailments they may have and how these other ailments may affect their treatment and prognosis. For this reason, researchers at the Mid America Heart Institute are conducting this research to find out how genes affect heart disease and recovery following angioplasty. The study will include patients with diabetes in order to determine if their genes are different from patients without diabetes.

A total of 1,607 patients were enrolled. There were 2 groups of patients selected for this study. The first group of patients included into the study will be those that are scheduled to have a diagnostic angiogram only. The second group of patients were those that had along with the angiogram a percutaneous transluminal coronary angioplasty, PTCA and or the use of a device called a coronary "stent", designed to help prop open the artery and to help avoid collapse. Samples for both groups will be stored for 30 years. After this time, all samples will be destroyed. Ultimately, we are hopeful that we will identify genes that will identify groups of patients at risk for heart disease.

A single-center prospective registry which enrolled 1,607 patients. Following informed consent, patients underwent coronary angiography and/or percutaneous coronary intervention. This project was funded by an institution grant, philanthropy, industry, and a grant from the American Diabetes Association. The long-term goal is to better understand the biological underpinnings associated with diabetic atherosclerosis and vascular risk attributable to diabetes. All patients also provided informed consent for blood banking. Blood samples were collected at baseline (fasting) and in patients undergoing PCI (random) at 2,8 and 16 hours following arterial injury. These samples were separated in aliquots of 12 x1000µL, 10x500µL EDTA plasma, 2x1,000 µL and 20x200 µL of buffy coat (baseline only) and 2x1,000 µL of RBCs (baseline only). This protocol was designed to perform multiple biomarker studies as it avoids multiple freeze thaw cycles. A plaque imaging sub-study using the IVUS-VH software platform to characterize plaque tissue enrolled 209 patients.

Eligibility Criteria:
Inclusion Criteria:

* Male or female gender
* Diabetes mellitus or no diabetes mellitus
* Candidate for percutaneous coronary intervention
* Informed consent
Opiate Detoxification Using the Combined Hemoperfusion-hemodialysis

The purpose of this study is to determine whether combined hemoperfusion-hemodialysis treatment is an alternative drug-free, effective, and safe treatment for opiate detoxification.

Drug abuse remains a major society problem in our community and is also a major health problem in our modern society. Thus, education to prevent the young generation to avoid drug abuse and detoxification to help those to quite from the drug abuse are two major key steps in the controlling drug abuse program.

Currently, medications for opiate detoxification, such as methadone, are commonly used worldwide. However, methadone is also an addictive medication. When it is stopped suddenly, patients usually produce unpleasant withdrawal symptoms. Meanwhile, methadone is also potentially to be abused too. Thus, it is urgently needed to seek an alternative safer, effective, drug-free method for opiate detoxification. Based on our clinical observation, the timely clearance of toxicities from the body or blood is a safe and effective detoxification method. Thus, we hypothesized that the use of combined hemoperfusion-hemodialysis may be an alternative drug-free, effective, and safe treatment for opiate detoxification. This will be tested in patients who have severe drug abuse and are under custodial conditions by a daily combined hemoperfusion-hemodialysis for 3 days. The efficacy and safety of the hemoperfusion-hemodialysis will be compared to a 10 day standard methadone detoxification treatment.

Eligibility Criteria:
Inclusion Criteria:

* Be fulfilled DSM-IV criteria(American Psychiatric Association) for opiate dependence.
* A history of current dependence on heroin, which was supported by laboratory results from urine drug screening, using both chromatographic and radioimmunoassay methods.
* Opioid dependent patients who inject heroin from 0.5g to 1.0g daily by veins for at least 1 year.
* Haven't received methadone treatment for at least 2 months before entry to this study.
* Be able to understand and have signed the informed consent.

Exclusion Criteria:

* Take heroin for the first time.
* Positive for HIV.
* The function of cruor or hemorrhage is badly damaged.
* The number of platelets is lower than 70×10\*9.
* Co-dependent on substances other than opiates (including alcohol, benzodiazepines, cocaine, or amphetamines).
* Methadone dose requirement is over 70 mg/day as determined by the 3-day dose assessment period.
* Have serious physical illness or major psychiatric illness.
* Pregnant woman.
Comparison of Treatment Effect of Chinese Medicine and Western Medicine on Depression in China and America

Comparison of different assessment methods to evaluate the treatment efficacy of Chinese medicine on minor and mild depression.

Significant differences show on the evaluation of treatment efficacy of Chinese medicine on depression in China and America. Choose minor and mild depression patients as trials. One hundred and sixty trials will be included and randomly divided into Chinese medicine group (n=40), acupuncture group (n=40), traditional Chinese medicine psychology group (n=40) and physical treatment group (n=40). Time points of assessment are before treatment, 1 week, 2 weeks, 4weeks, 6 weeks and 12 weeks post treatment.The assessment tools are series of psychological questionnaires. And study the mechanism of treatment efficacy assessment variances by different methods.

Eligibility Criteria:
Inclusion Criteria:

* According with ICD-10 criteria of depression;
* Age 16-70;
* Antidepressant and other Psychiatric drugs have not been had two weeks before the trial, or the drugs above had been used but have cleaning period of two weeks;
* Level of education is higher than junior middle school;
* Course of disease is more than two weeks;
* Volunteer to join and Signed the informed consent

Exclusion Criteria:

* Pregnancy or lactation;
* Severe depression or have serious suicidal tendencies
* long distance or other causes who can not adherence to treatment